Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05930275




Registration number
NCT05930275
Ethics application status
Date submitted
27/06/2023
Date registered
5/07/2023
Date last updated
10/06/2024

Titles & IDs
Public title
Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
Scientific title
A Multi-country, Prospective, Post-marketing Study of UPadacitinib Evaluating Speed of Onset and Durability of Effectiveness for Patients With Moderate to Severe Crohn's Disease for 3 Years in Real-world Clinical Practice (UPlift)
Secondary ID [1] 0 0
P23-899
Universal Trial Number (UTN)
Trial acronym
UPlift
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Crohn's Disease 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Inflammatory bowel disease
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 0 0 0 0
Crohn's disease

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Upadacitinib - Participants will receive upadacitinib as prescribed by their physician according to local label.
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to Achieve First Clinical Response (CR) per Patient-Reported Outcome 2 (PRO2) (Daily CR-PRO)
Timepoint [1] 0 0
Up to Week 12
Primary outcome [2] 0 0
Percentage of Participants Achieving Clinical Remission per Harvey Bradshaw Index (HBI) Among those with Clinical Response-Harvey Bradshaw Index (CR-HBI) at End of Induction Therapy
Timepoint [2] 0 0
At Week 52

Eligibility
Key inclusion criteria
- A diagnosis of moderate-to-severe crohn's disease (CD).

- Participants initiating upadacitinib at the clinician's discretion as part of their
routine clinical care; the decision to administer upadacitinib must be made prior to
and independent of recruitment into the study.

- Participants prescribed upadacitinib in accordance with the approved local label.

- Able to understand and communicate with the investigator and comply with the
requirements of the study.

- Willing to continue with study documentation after cessation of upadacitinib.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Any contraindication to upadacitinib.

- Previously exposure to upadacitinib in a clinical trial.

- Currently participating in interventional research (not including non-interventional
study, post-marketing observational study (PMOS) , or registry participation).

- Initiation of upadacitinib prior to enrollment.

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
19/02/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/09/2028
Actual
Sample size
Target
1200
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
Macquarie University Hospital /ID# 258574 - Macquarie Park
Recruitment hospital [2] 0 0
The Queen Elizabeth Hospital /ID# 258536 - Woodville South
Recruitment hospital [3] 0 0
Monash Medical Centre /ID# 258538 - Clayton
Recruitment hospital [4] 0 0
The Alfred Hospital /ID# 258537 - Melbourne
Recruitment postcode(s) [1] 0 0
2113 - Macquarie Park
Recruitment postcode(s) [2] 0 0
5011 - Woodville South
Recruitment postcode(s) [3] 0 0
3168 - Clayton
Recruitment postcode(s) [4] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
Canada
State/province [1] 0 0
British Columbia
Country [2] 0 0
Canada
State/province [2] 0 0
Ontario
Country [3] 0 0
China
State/province [3] 0 0
Guangdong
Country [4] 0 0
France
State/province [4] 0 0
Alpes-Maritimes
Country [5] 0 0
France
State/province [5] 0 0
Auvergne-Rhone-Alpes
Country [6] 0 0
France
State/province [6] 0 0
Bouches-du-Rhone
Country [7] 0 0
France
State/province [7] 0 0
Gironde
Country [8] 0 0
France
State/province [8] 0 0
Haute-Garonne
Country [9] 0 0
France
State/province [9] 0 0
Herault
Country [10] 0 0
France
State/province [10] 0 0
Ile-de-France
Country [11] 0 0
France
State/province [11] 0 0
Marne
Country [12] 0 0
France
State/province [12] 0 0
Nord
Country [13] 0 0
France
State/province [13] 0 0
Pays-de-la-Loire
Country [14] 0 0
France
State/province [14] 0 0
Pyrenees-Atlantiques
Country [15] 0 0
France
State/province [15] 0 0
Rhone
Country [16] 0 0
France
State/province [16] 0 0
Somme
Country [17] 0 0
France
State/province [17] 0 0
Cagnes Sur Mer
Country [18] 0 0
France
State/province [18] 0 0
Cholet
Country [19] 0 0
France
State/province [19] 0 0
Dreux
Country [20] 0 0
France
State/province [20] 0 0
Le Kremlin Bicetre
Country [21] 0 0
France
State/province [21] 0 0
Paris
Country [22] 0 0
France
State/province [22] 0 0
Rennes
Country [23] 0 0
France
State/province [23] 0 0
St-Priest-en-Jarez
Country [24] 0 0
France
State/province [24] 0 0
Strasbourg cedex
Country [25] 0 0
Germany
State/province [25] 0 0
Nordrhein-Westfalen
Country [26] 0 0
Germany
State/province [26] 0 0
Schleswig-Holstein
Country [27] 0 0
Germany
State/province [27] 0 0
Berlin
Country [28] 0 0
Germany
State/province [28] 0 0
Hamburg
Country [29] 0 0
Germany
State/province [29] 0 0
Herne
Country [30] 0 0
Germany
State/province [30] 0 0
Lueneburg
Country [31] 0 0
Germany
State/province [31] 0 0
Magdeburg
Country [32] 0 0
Germany
State/province [32] 0 0
Tostedt
Country [33] 0 0
Greece
State/province [33] 0 0
Attiki
Country [34] 0 0
Greece
State/province [34] 0 0
Athens
Country [35] 0 0
Hungary
State/province [35] 0 0
Hajdu-Bihar
Country [36] 0 0
Hungary
State/province [36] 0 0
Vas
Country [37] 0 0
Hungary
State/province [37] 0 0
Budapest
Country [38] 0 0
Hungary
State/province [38] 0 0
Szeged
Country [39] 0 0
Japan
State/province [39] 0 0
Hokkaido
Country [40] 0 0
Japan
State/province [40] 0 0
Asahikawa
Country [41] 0 0
Japan
State/province [41] 0 0
Nishinomiya
Country [42] 0 0
Japan
State/province [42] 0 0
Saga
Country [43] 0 0
Japan
State/province [43] 0 0
Toyama
Country [44] 0 0
Spain
State/province [44] 0 0
Cordoba
Country [45] 0 0
Spain
State/province [45] 0 0
Granada

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
AbbVie
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal
tract. This study will assess how safe and effective upadacitinib is in treating moderately
to severely active CD in real world. Speed of onset and durability of effectiveness will be
assessed.

Upadacitinib is a drug approved for the treatment of CD. All study participants will receive
upadacitinib as prescribed by their study doctor in accordance with approved local label.
Approximately 1200 participants will be enrolled in approximately 230 sites across the world.

Participants will receive upadacitinib as prescribed by their physician according to their
routine clinical practice and local label. Participants will be followed for up to 3 years.

There is expected to be no additional burden for participants in this trial. Study visits may
be conducted on-site or virtually as per standard of care.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05930275
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
ABBVIE INC.
Address 0 0
AbbVie
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Tanja Plath
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
tanja.plath@abbvie.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05930275